A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

Part of paid clinical trials in Anchorage, Alaska.

Sponsor
Bristol-Myers Squibb
Study ID
NCT06855771
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Carcinoma, Non-Small-Cell Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986504 — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the safety and efficacy of Navlimetostat (BMS-986504) monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion after progression on prior therapies.

Key Dates

Start date
Sep 9, 2025
Status verified
Jun 2026
Primary completion
Dec 29, 2028
Completion
Dec 30, 2031

Study Design

Enrollment
130 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A: BMS-986504 Dose 1
  • Experimental: Arm B: BMS-986504 Dose 2

Primary Outcome Measure

Number of participants who achieve Objective Response (OR) utilizing the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [ Time Frame: Up to 3 years after the last participant's last dose of study treatment ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (12)

FacilityCityStateZIPSite coordinators
Alaska Oncology and HematologyAnchorageAlaska99508
Steven Liu, Site 0088
907-257-9851
Local Institution - 0099BoiseIdaho83712
Site 0099
Dana-Farber Cancer InstituteBostonMassachusetts02215
Pasi Janne, Site 0090
617-632-6036
Karmanos Cancer InstituteDetroitMichigan48201
Hirva Mamdani, Site 0100
909-525-0093
Washington University School of MedicineSt LouisMissouri63110
Anjali Rohatgi, Site 0104
314-747-1171
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065
Kathryn Arbour, Site 0018
646-608-3792
Local Institution - 0079ShirleyNew York11967
Site 0079
Gabrail Cancer CenterCantonOhio44718
Nashat Gabrail, Site 0091
330-417-8231
Oregon Health and Science UniversityPortlandOregon97239
Jeremy Cetnar, Site 0103
503-494-3840
Providence Portland Medical CenterPortlandOregon97213
Rachel Sanborn, Site 0098
503-215-5696
Fred Hutchison Cancer CenterSeattleWashington98109
Lei Deng, Site 0078
206-606-4801
Medical College of WisconsinMilwaukeeWisconsin53226
Jonathan Thompson, Site 0084
920-202-1555

Find similar trials in Anchorage, AK

By research site
Alaska Oncology and Hematology· Anchorage, AKLocal Institution - 0099· Boise, IDDana-Farber Cancer Institute· Boston, MAKarmanos Cancer Institute· Detroit, MIWashington University School of Medicine· St Louis, MOMemorial Sloan Kettering Cancer Center· New York, NY

Related Studies